NTT DATA Partners with Palo Alto Networks to Deliver AI-Driven Cloud-to-Edge Cybersecurity to Enterprise Clients
28.10.2024 14:00:00 CET | Business Wire | Press Release
NTT DATA, a global digital business and IT services leader, today announced an expanded partnership with Palo Alto Networks, the global cybersecurity leader, to help global enterprises safeguard their digital infrastructures from emerging cybersecurity threats, spanning from the cloud to the farthest edge of enterprise environments.
The collaboration introduces NTT DATA’s Managed Extended Detection Response Service (MXDR), offering continuous threat monitoring, detection and rapid response capabilities. Leveraging AI and machine learning, the service provides visibility across networks, edge and cloud environments, enabling organizations to stay ahead of evolving cyberthreats.
The service is powered by Palo Alto Networks Cortex XSIAM, the industry’s leading security operations center (SOC) platform. Cortex XSIAM is an AI-driven platform that transforms the SOC, by harnessing the power of AI and automation to simplify operations, stop threats at scale and accelerate incident remediation.
These combined capabilities are designed to help enterprises strengthen their cyber resilience by integrating innovative technologies and threat intelligence with global security expertise, significantly reducing the time needed to detect and respond to sophisticated cyber threats. Clients benefit from a unified view of data and security operations on a single platform to streamline operations and prevent threats.
According to Gartner®, “worldwide end-user spending on information security is projected to total US$212 billion in 2025, an increase of 15.1% from 2024.”* NTT DATA’s new MXDR service is designed to help clients enhance protection across their digital landscape while reducing complexity and costs of fragmented security systems.
“Many organizations rely on fragmented security systems, making it harder to detect advanced threats, and react quickly,” said Sheetal Mehta, Global Head of Cybersecurity, NTT DATA, Inc. “By partnering with Palo Alto Networks, we’re delivering a unified solution that strengthens cyber resilience, streamlines security operations and improves overall agility.”
“Organizations today are facing an unprecedented volume of sophisticated cyber threats, across their entire operations,” said Kristy Friedrichs, Chief Partnerships Officer, Palo Alto Networks. “With NTT DATA, we are helping organizations transform their SOC through platformization with XSIAM and expert services, delivering a unified solution that ensures customers can modernize and protect their operations with confidence.”
NTT DATA’s new MXDR service offers 24x7 incident detection and response, supported by a global operations team, AI-driven threat intelligence orchestration and automation. This highly modernized service leverages machine learning for advanced threat detection backed by a team of skilled information security managers, threat hunters, digital forensic experts and certified security professionals.
By integrating real-time threat intelligence into the heart of its operations, NTT DATA proactively protects clients from emerging risks in an ever-changing cybersecurity landscape. This allows customers to reduce operational complexity, improve resource management and lower the total cost of ownership (TCO).
Empowering industries to modernize with confidence
The NTT DATA and Palo Alto Networks partnership targets industries that rely on secure, connected environments, including manufacturing, chemical and pharmaceutical sectors. Key benefits include:
- Comprehensive Edge-to-Cloud Security: Full visibility into devices and networks, ensuring robust protection.
- AI-Powered Threat Detection: AI-driven detection and response identifies and mitigates threats at machine speed.
- Reduced Complexity and TCO: Truly a single platform, with one UI and one agent, that unifies multiple security services, simplifying the management of and drastically shortening response times.
- Resilience Against Downtime: Integrated and automated services ensure business continuity, global reach and innovation.
Today’s announcement represents another step forward in the strategic alliance between NTT DATA and Palo Alto Networks, positioning both companies as leaders in delivering secure, connected environments for global enterprises. With operations in 50 countries, NTT DATA offers local expertise alongside global cybersecurity solutions, supported by over 7,500 cybersecurity professionals with more than 260 technical certifications. With over 15,000 security engagements, NTT DATA mitigates 2 billion security threats each year.
Learn more about NTT DATA and Palo Alto Networks here.
* Gartner Press Release, Gartner Forecasts Global Information Security Spending to Grow 15% in 2025, 28 August 2024, Gartner, Inc. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have diverse experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at nttdata.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028913666/en/
Contacts
Lori Bosio
Senior Director External Communications, NTT DATA, Inc.
lori.bosio@global.ntt
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom